It is the cache of http://www.dovepress.com/management-of-peripheral-arterial-disease-in-the-elderly-focus-on-cilo-a230. It is a snapshot of the page. The current page could have changed in the meantime.
Tip: To quickly find your search term on this page, press Ctrl+F or ⌘-F (Mac) and use the find bar.

skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

14789

Management of peripheral arterial disease in the elderly: focus on cilostazol



Review

(6041) Total Article Views


Authors: Travis M Falconer, John W Eikelboom, Graeme J Hankey, Paul E Norman

Published Date March 2008 Volume 2008:3(1) Pages 17 - 23
DOI: http://dx.doi.org/10.2147/CIA.S1735

Travis M Falconer1, John W Eikelboom2, Graeme J Hankey3, Paul E Norman1

1School of Surgery, University of Western Australia, Fremantle Hospital, Western Australia; 2Department of Medicine, McMaster University, Hamilton, Canada; 3Department of Neurology, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia

Abstract: Symptomatic and asymptomatic peripheral arterial disease (PAD) is a common problem in the elderly. The management of PAD includes the prevention of cardiovascular events and relief of symptoms – most commonly intermittent claudication (IC). Both require treatment of the causes and consequences of atherothrombosis, but some strategies are more effective for prevention of cardiovascular events and others are more effective for the relief of symptoms. Priorities for the prevention of cardiovascular events include smoking cessation, exercise, antiplatelet therapy, and the treatment of dyslipidemia, hypertension, and diabetes. Walking time and ability are improved by exercise. The benefit of numerous drugs in the treatment of IC has been assessed. The results have generally been disappointing, but there is some evidence that statins and cilostazol (an inhibitor of phosphodiesterase 3) are of benefit. Meta-analyses suggest that cilostazol increases maximum walking distance by 40%–50% and improves other objective measures of walking. The safety profile of cilostazol in patients with PAD appears to be acceptable although the mechanism for its effect on IC is unclear. In addition to risk factor management, treatment with cilostazol should be considered in patients with disabling IC.

Keywords: peripheral arterial disease, intermittent claudication, risk factors, cilostazol




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read: